Followers | 185 |
Posts | 10548 |
Boards Moderated | 0 |
Alias Born | 11/23/2007 |
Saturday, November 21, 2015 10:53:50 PM
Recent ESPR News
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:14:43 PM
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia • GlobeNewswire Inc. • 05/20/2024 10:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 07:08:17 PM
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/10/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:31:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:50:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:29:53 AM
- Esperion Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- Esperion to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Esperion to Report First Quarter 2024 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity • GlobeNewswire Inc. • 04/07/2024 06:45:00 PM
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 • GlobeNewswire Inc. • 03/25/2024 08:00:00 PM
- U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • Business Wire • 03/22/2024 10:26:00 PM
- U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • GlobeNewswire Inc. • 03/22/2024 07:10:20 PM
- CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events • GlobeNewswire Inc. • 03/22/2024 03:04:39 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 02:19:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:23:29 PM
- Esperion Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/27/2024 11:00:00 AM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/16/2024 09:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:50:20 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM